<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782648</url>
  </required_header>
  <id_info>
    <org_study_id>TB-LSG-01</org_study_id>
    <nct_id>NCT04782648</nct_id>
  </id_info>
  <brief_title>Transit Bipartition After Sleeve Gastrectomy</brief_title>
  <acronym>TB-LSG</acronym>
  <official_title>Transit Bipartition to Promote Weight Loss After Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective analysis of 100 morbidly obese patients who underwent a transit bipartition&#xD;
      (TB) procedure (&quot;Single Anastomosis Sleeve Ileal bypass&quot;) for inadequate weight loss or&#xD;
      weight recidivism after a previous sleeve gastrectomy. Data were collected prospectively in&#xD;
      strictly pseudonymous form. The primary endpoint of the study is weight loss at 1, 3, 6 and&#xD;
      12 months after TB. A subgroup analysis evaluates the effect of the length of the common&#xD;
      channel. Secondary endpoints include impact on obesity related comorbidities (type 2&#xD;
      diabetes, hypertension, sleep apnea, gastroesophageal reflux) as well as safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective data base of 100 consecutive morbidly obese patients who had undergone transit&#xD;
      bipartition (TB, also termed &quot;Single Anastomosis Sleeve Ileal bypass&quot;) after a previous&#xD;
      sleeve gastrectomy (LSG). Inclusion criteria were TB for excess weight loss (EWL) &lt; 50% ≥ 12&#xD;
      months post LSG or weight recidivism of &gt; 5 kg/qm with a body mass index (BMI) &gt; 30 kg/qm.&#xD;
      Patients with endocrine disorders other than type 2 diabetes mellitus (T2D), major&#xD;
      psychiatric disorders, American Society of Anesthesiologists (ASA) III and higher or pregnant&#xD;
      patients were excluded from the study. Data were prospectively collected in strictly&#xD;
      pseudonymous form. Follow up time points were at 1, 3, 6 and 12 months following TB. The&#xD;
      primary endpoint of the study is weight loss at 1, 3, 6 and 12 months after TB. A subgroup&#xD;
      analysis evaluates the effect of the length of the common channel. Secondary endpoints&#xD;
      include impact on obesity related comorbidities such as T2D, hypertension, sleep apnea,&#xD;
      gastroesophageal reflux as well as safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">December 20, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percent excess weight loss (EWL)</measure>
    <time_frame>12 months</time_frame>
    <description>preoperative weight-current weight / preoperative weight-ideal weight x 100 (ideal weight defined as BMI 25 kg/qm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with improvement of type 2 diabetes</measure>
    <time_frame>12 months</time_frame>
    <description>number of patients with HbA1c &lt;6 %, fasting blood glucose &lt;100 mg/dL in the absence of antidiabetic medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with improvement of gastro-esophageal reflux (GERD)</measure>
    <time_frame>12 months</time_frame>
    <description>number of patients with no GERD symptoms, reflux symptom score (RSI) &lt; 13 in the absence of medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with improvement of hypertension</measure>
    <time_frame>12 months</time_frame>
    <description>number of patients with normotensive blood pressure (&lt;120/80 mmHg) in the absence of antihypertensive medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with improvement of sleep apnoea</measure>
    <time_frame>12 months</time_frame>
    <description>number of patients with discontinued use of sleep apnea treatment (continuous positive airway pressure - CPAP) based on improved symptoms and Obstructive Sleep Apnoea (OSA) screening.</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Weight Gain</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transit bipartition</intervention_name>
    <description>transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy</description>
    <other_name>SASI bypass</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Morbidly obese patients (BMI &gt; 30) who underwent transit bipartition (SASI bypass) for&#xD;
        inadequate weight loss or weight regain after laparoscopic sleeve gastrectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TB for excess weight loss (EWL) &lt; 50% ≥ 12 months post LSG or weight recidivism of &gt; 5&#xD;
             kg/qm with a body mass index (BMI) &gt; 30 kg/qm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  endocrine disorders other than T2DM, major psychiatric disorders, ASA ≥ III,&#xD;
             pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Reiser, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Gastroenterology, Klinikum-Vest GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Vest GmbH</name>
      <address>
        <city>Recklinghausen</city>
        <state>NRW</state>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Markus Reiser, M.D.</investigator_full_name>
    <investigator_title>Chief Dept. Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>weight regain</keyword>
  <keyword>sleeve gastrectomy</keyword>
  <keyword>SASI bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

